Sanofi (NASDAQ:SNY) Upgraded by StockNews.com to Strong-Buy

Sanofi (NASDAQ:SNY) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.

Separately, Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Down 1.3 %

Shares of SNY stock traded down $0.70 on Friday, reaching $52.40. 1,994,415 shares of the company’s stock traded hands, compared to its average volume of 2,153,594. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.72. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The company has a market capitalization of $132.71 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 1.59 and a beta of 0.59. The business’s 50 day moving average price is $49.21 and its two-hundred day moving average price is $48.71.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, April 25th. The company reported $0.96 EPS for the quarter, meeting analysts’ consensus estimates of $0.96. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. The firm had revenue of $11.36 billion for the quarter, compared to the consensus estimate of $11.75 billion. On average, equities analysts forecast that Sanofi will post 4.14 earnings per share for the current year.

Institutional Investors Weigh In On Sanofi

A number of hedge funds and other institutional investors have recently bought and sold shares of SNY. Boston Partners increased its stake in shares of Sanofi by 0.3% in the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after buying an additional 33,657 shares during the period. Bank of New York Mellon Corp lifted its holdings in Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after acquiring an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after acquiring an additional 1,190,141 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of Sanofi by 16.2% in the second quarter. Raymond James & Associates now owns 2,689,876 shares of the company’s stock valued at $130,513,000 after purchasing an additional 374,621 shares in the last quarter. Finally, Equity Investment Corp lifted its holdings in shares of Sanofi by 23.0% in the first quarter. Equity Investment Corp now owns 2,393,474 shares of the company’s stock valued at $116,323,000 after purchasing an additional 447,872 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.